Predictors of Mortality in Patients with Emphysema and Severe Airflow Obstruction
Limited data exist describing risk factors for mortality in patients having predominantly emphysema. A total of 609 patients with severe emphysema (ages 40-83 yr; 64.2% male) randomized to the medical therapy arm of the National Emphysema Treatment Trial formed the study group. Cox proportional haza...
Saved in:
Published in | American journal of respiratory and critical care medicine Vol. 173; no. 12; pp. 1326 - 1334 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York, NY
Am Thoracic Soc
15.06.2006
American Lung Association American Thoracic Society |
Subjects | |
Online Access | Get full text |
ISSN | 1073-449X 1535-4970 |
DOI | 10.1164/rccm.200510-1677OC |
Cover
Loading…
Summary: | Limited data exist describing risk factors for mortality in patients having predominantly emphysema.
A total of 609 patients with severe emphysema (ages 40-83 yr; 64.2% male) randomized to the medical therapy arm of the National Emphysema Treatment Trial formed the study group. Cox proportional hazards regression analysis was used to investigate risk factors for all-cause mortality. Risk factors examined included demographics, body mass index, physiologic data, quality of life, dyspnea, oxygen utilization, hemoglobin, smoking history, quantitative emphysema markers on computed tomography, and a modification of a recently described multifunctional index (modified BODE).
Overall, high mortality was seen in this cohort (12.7 deaths per 100 person-years; 292 total deaths). In multivariate analyses, increasing age (p=0.001), oxygen utilization (p=0.04), lower total lung capacity % predicted (p=0.05), higher residual volume % predicted (p=0.04), lower maximal cardiopulmonary exercise testing workload (p=0.002), greater proportion of emphysema in the lower lung zone versus the upper lung zone (p=0.005), and lower upper-to-lower-lung perfusion ratio (p=0.007), and modified BODE (p=0.02) were predictive of mortality. FEV1 was a significant predictor of mortality in univariate analysis (p=0.005), but not in multivariate analysis (p=0.21).
Although patients with advanced emphysema experience significant mortality, subgroups based on age, oxygen utilization, physiologic measures, exercise capacity, and emphysema distribution identify those at increased risk of death. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 Correspondence and requests for reprints should be addressed to Fernando J. Martinez, M.D., M.S., 1500 East Medical Center Drive, 3916 Taubman Center, Ann Arbor, MI 48109-0360. E-mail: fmartine@umich.edu Supported by contracts with the National Heart, Lung, and Blood Institute (N01HR76101, N01HR76102, N01HR76103, N01HR76104, N01HR76105, N01HR76106, N01HR76107, N01HR76108, N01HR76109, N01HR76110, N01HR76111, N01HR76112, N01HR76113, N01HR76114, N01HR76115, N01HR76116, N01HR76118, and N01HR76119), the Centers for Medicare and Medicaid Services, and the Agency for Healthcare Research and Quality. This article has an online supplement, which is accessible from this issue's table of contents at www.atsjournals.org Originally Published in Press as DOI: 10.1164/rccm.200510-1677OC on March 16, 2006 Conflict of Interest Statement: F.J.M. has received less than $10,000 from Intermune, and has had no consulting or speaker bureau activities with Intermune during the present calendar year. He was previously a co-investigator in the GIPF-007 study. He has been a site principal investigator at the University of Michigan for the BUILD 1 study sponsored by Actelion, and his total personal compensation was less than $10,000. He has, in the past, been a member of the Encysive steering committee for a selective endothelin antagonist and of the Co-Therix steering committee for an inhaled vasodilator. He has been a member of several Pfizer advisory boards, CME committees, and the Speaker's Bureau for Pfizer, relating exclusively to COPD, with total compensation greater than $10,000, but less than $20,000. He has been a member of several Boehringer advisory boards, CME committees, and the Speaker's Bureau for Boehringer Ingelheim, relating exclusively to COPD, with total compensation greater than $10,000, but less than $20,0000. G.F. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. J.L.C. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. G.C. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. G.W. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.F. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.M.D. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. J.B. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. F.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. B.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. Z.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. P.D. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. E.H. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. R.W. received consulting fees from GlaxoSmithKline, Pfizer, Sanofi-Aventis, Emphasys, and Spiration in the past 3 yr for research oversight and review committees. He has served on advisory boards for Boehringer-Ingelheim, Pfizer, GlaxoSmithKline, Hill-Rom, Otsuka, Ortho, and Amgen. He has also received research grants from Boehringer-Ingleheim, Ostuka, and Pfizer. Conflicts of interest regarding human research are managed by the Johns Hopkins University. |
ISSN: | 1073-449X 1535-4970 |
DOI: | 10.1164/rccm.200510-1677OC |